MAXimizing Flow Diversion Effect On the Treatment of Large Intracranial Aneurysms With Embolization Devices

Intracranial Aneurysm Clinical Trial

— MAX-PIPE  

Official title:

MAX-PIPE Registry - Maximizing Flow Diversion Effect On The Treatment of Large Intracranial Aneurysms With PIPEline Flex Embolization Devices Using Optical Flow Imaging Software "AneurysmFlow"

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03161769
• Other study ID #: TWH -Version 4.0 July 13 2016
• Status: Recruiting
• Start date: April 21, 2017
• Est. completion date: September 1, 2019

Study information

• Verified date: October 2018
• Source: University Health Network, Toronto
• Contact: Vitor Pereira, MD
• Phone: 416-603-5800
• Email: vitor.pereira[@]uhn.ca
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Investigate the ability of the intra-operative, intra-aneurysmal flow evaluation to assist with the treatment of intracranial large aneurysms using Embolization Device(s)

Description:

The Division of Neuroradiology at UHN (Toronto Western Hospital) would like to initiate a single center registry study on the treatment of large intracranial aneurysms with PIPEline[tm] flex embolization devices using optical flow imaging software, "AneurysmFlow". The study team will consent patients diagnosed with unruptured brain / intracratial aneurysms IA(s) . The selected patients ,who booked for elective brain aneurysm repair/endovascular treatment with Flow diverter devices (FDS) called Pipeline embolization devices (PED), will qualify for registry participation . During the PED procedure, the study team will be using AneurysmFlow software to calculate a new metric called the MAFA ratio (Mean Aneurysm Flow Amplitude). By calculating the MAFA ratios intra-operatively, the interventionalist can adapt the therapeutic strategy in order to maximize the flow diverting effect on inducing complete aneurysm occlusions (thrombosis). Additionally, the purpose of this study is to further expand the body of clinical knowledge concerning the relationship between blood flow metrics as determined by the AneurysmFlow software and clinical outcome in patients undergoing treatment for intracranial aneurysms (IAs) with Pipeline and Pipeline Flex embolization devices. The study team aims to collect data at a 12 month follow-up period for each patient

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: September 1, 2019
• Est. primary completion date: September 1, 2019
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subject with unruptured, large (=8mm) saccular aneurysm(s) located in the anterior intracranial circulation and suitable for an endovascular treatment with a Flow Diverter Stent.

2. Subject has signed an institutionally approved research informed consent form.

3. Subject = 18 years old.

Exclusion Criteria:

1. Subject with non-saccular brain aneurysm (s) such as:- dissecting; fusiform; atherosclerotic; mycotic; bifurcational.

2. Subject underwent a prior target brain aneurysm treatment with either endovascular (stenting, coiling) or surgical (clipping) techniques.

3. The endovascular treatment of subject's target aneurysm(s) was assisted with coils or intracranial stents (non-FDS) before the AneurysmFlow calculations.

4. Subject with partially thrombosed or recanalized target brain aneurysm(s).

5. Subject had prior significant or severe allergy to intra-arterial contrast medium uncontrolled by pre-procedure medications.

6. Subject with severe kidney disease (e-GFR < 60).

7. Subject is not willing (or not able) to attend post FDS insertion follow up clinic visits requiring DSA, head MRI or CTA imaging.

Related Conditions & MeSH terms

• Aneurysm
• Intracranial Aneurysm

Intervention

Procedure:
• Neurovascular treatment of intracranial aneurysms
Endovascular treatment of intracranial aneurysms using flow diverting stents

Device:
• AneurysmFlow image processing software
Software to process and display images of intracranial aneurysm treatment using flow diverting stents.

Locations

Country	Name	City	State
Canada	Toronto Western Hospital - University Health Network	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
University Health Network, Toronto	Philips Healthcare

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with complete aneurysm occlusion at 12 months based on contrast agent volume measurement in angiography.	=86% complete aneurysm occlusion rate after 12 months post-treatment using optical flow analysis with a MAFA threshold ratio of 0.89, measured with an image processing tool.	1 year
Secondary	Number of participants with complete aneurysm occlusion at 6 months based on contrast agent volume measurement in angiography.	=74% complete aneurysm occlusion rate after 6 months post-treatment using optical flow analysis with a MAFA threshold ratio of 0.89, measured with an image processing tool.	6 months
Secondary	High sensitivity and specificity (> 80%) of the MAFA ratio to determine aneurysm occlusion rates based on ROC statistical calculations.	Data collected from the registry will be used to help determine a new, more optimal MAFA ratio threshold for predicting post-FDS aneurysm occlusion at 12 months post-treatment based on receiver operating characteristic (ROC) statistical curves.	1 year
Secondary	Number of participants with treatment complications as assessed by an electronic patient record.	Predictability of the MAFA ratio for treatment complications (aneurysm rupture, in-stent thrombosis, mass effect, using a correlation analysis.	1 year